TheREnantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis

Clinical Epidemiologic Profile of a Cohort of Post–Kala-Azar Dermal Leishmaniasis Patients in Bihar, India

(2012) Vidya Nand Rabi Das et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis

(2012) S. Wyllie et al.   Science Translational Medicine

Fexinidazole: A Potential New Drug Candidate for Chagas Disease

(2012) Maria Terezinha Bahia et al.   PLoS Neglected Tropical Diseases

Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping Sickness

(2011) Marcel Kaiser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles

(2011) Meera Gurumurthy et al.   FEBS Journal

Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites

(2011) Belinda S. Hall et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design

(2011) Nicholas A. Meanwell   JOURNAL OF MEDICINAL CHEMISTRY

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis

(2010) A. Y. Sokolova et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis

(2010) Zahoor Ahmad et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis

(2010) Deuan C. Jones et al.   BIOCHEMICAL PHARMACOLOGY

Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

(2010) Els Torreele et al.   PLoS Neglected Tropical Diseases

Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects

(2009) A. M. Ginsberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Developments in the treatment of visceral leishmaniasis

(2009) Margriet Leontine den Boer et al.   EXPERT OPINION ON EMERGING DRUGS

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

(2009) Gerardo Priotto et al.   LANCET

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis

(2008) E. Nuermberger et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A comparative study of methylglyoxal metabolism in trypanosomatids

(2008) Neil Greig et al.   FEBS Journal

PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

(2008) R. Singh et al.   SCIENCE